Last 33 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -6.92 | — | — | — | — | — | — | — | 2.10 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 28.08 | 1.90 | 0.24 | 0.78 | 2.56 | 8.33 | 2.31 | 6.67 | 0.58 | 3.11 | 6.74 | 5.35 | 13.29 |
| — | -77.2% | -89.8% | -88.4% | +345.5% | +168.2% | -65.6% | +24.7% | -95.7% | +7.5% | +209.5% | -67.0% | -17.6% | |
| P/B Ratio | 35.26 | — | — | — | 3.40 | 2.55 | 1.56 | 3.54 | 1.75 | 1.87 | 1.81 | 1.46 | 2.11 |
| — | — | — | — | +94.7% | +36.4% | -13.8% | +142.1% | -17.3% | +48.0% | +55.0% | -15.6% | -22.3% | |
| P/FCF | — | — | — | — | — | — | 6.84 | — | 5.18 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | 1.26 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | 1.02 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Sutro Biopharma, Inc.'s operating margin was -499.9% in Q3 2025, down 494.7 pp QoQ and up 297.2 pp YoY. The trailing four-quarter average of -334.9% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 93.0% | 86.5% | 100.0% | 100.0% | -299.5% | 100.0% | -399.7% |
| — | 0.0% | +7.5% | +15.7% | 0.0% | 0.0% | +131.1% | -13.5% | +125.0% | 0.0% | -399.5% | +124.5% | -121.0% | |
| Operating Margin | -384.3% | -499.9% | -5.2% | -393.8% | -440.7% | -797.2% | -189.4% | -435.0% | 37.9% | -260.1% | -443.5% | -333.3% | -570.2% |
| — | +37.3% | +97.2% | +9.5% | -1261.3% | -206.5% | +57.3% | -30.5% | +106.7% | -208.3% | -543.0% | +49.8% | -73.4% | |
| Net Margin | -366.6% | -586.6% | -18.0% | -436.6% | -489.2% | -572.6% | -186.8% | -447.5% | 27.3% | -291.2% | -370.0% | -394.9% | -400.8% |
| — | -2.4% | +90.3% | +2.4% | -1890.8% | -96.6% | +49.5% | -13.3% | +106.8% | -275.8% | -299.6% | +40.5% | -12.0% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -234.2% | — | — | -808.6% | -93.0% | -37.0% | -38.4% | -47.0% | 23.7% | -36.9% | -22.7% | -24.9% | -15.5% |
| — | — | — | -1620.1% | -492.1% | -0.4% | -69.4% | -89.0% | +253.1% | -315.5% | -87.0% | -50.4% | -8.9% | |
| ROA | -53.0% | -24.1% | -3.9% | -21.4% | -17.3% | -10.4% | -10.8% | -13.3% | 6.9% | -11.0% | -9.4% | -13.1% | -8.6% |
| — | -132.3% | +63.4% | -61.0% | -350.8% | +5.7% | -14.9% | -1.8% | +180.4% | -121.8% | -24.1% | -7.9% | +19.9% | |
| ROIC | -207.6% | — | -38.9% | — | -51.1% | -46.0% | -49.1% | -48.5% | 35.4% | -178.9% | -50.3% | -16.1% | -18.0% |
| — | — | +20.7% | — | -244.1% | +74.3% | +2.4% | -202.1% | +297.1% | -1988.2% | -652.4% | -44.8% | -102.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 18.0% YoY to 2.53x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 4.57 | — | — | — | 4.57 | 1.77 | 0.17 | 0.29 | 0.22 | 0.34 | 0.31 | 0.25 | 0.25 |
| — | — | — | — | +1934.7% | +420.8% | -44.5% | +14.0% | -11.3% | +47.4% | +18.4% | -4.5% | +11.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 0.75 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.60 | 2.53 | 3.12 | 2.16 | 2.60 | 3.09 | 3.41 | 4.46 | 4.50 | 5.18 | 6.14 | 5.11 | 5.31 |
| — | -18.0% | -8.6% | -51.6% | -42.1% | -40.3% | -44.4% | -12.8% | -15.3% | -12.9% | -17.5% | -13.4% | +1.4% | |
| Quick Ratio | 2.60 | 2.53 | 3.12 | 2.16 | 2.60 | 3.09 | 3.41 | 4.46 | 4.50 | 5.18 | 6.14 | 5.11 | 5.31 |
| — | -18.0% | -8.6% | -51.6% | -42.1% | -40.3% | -44.4% | -12.8% | -15.3% | -12.9% | -17.5% | -13.4% | +1.4% | |
| Interest Coverage | -7.67 | -4.66 | -0.35 | -6.44 | -7.51 | -8.59 | -5.38 | -6.02 | 4.94 | -5.07 | -13.76 | -14.15 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 33 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonSutro Biopharma, Inc.'s current P/E is -6.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Sutro Biopharma, Inc.'s current operating margin is -384.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Sutro Biopharma, Inc.'s business trajectory between earnings reports.